Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Drug Discovery,Pharmacology
Reference30 articles.
1. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review;Sanders;JAMA,2020
2. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding;Lu;Lancet,2020
3. A pneumonia outbreak associated with a new coronavirus of probable bat origin;Zhou;Nature,2020
4. Sex-based pharmacotherapy in acute care setting, a narrative review for emergency providers;Mehta;Am. J. Emerg. Med.,2020
5. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor;Hoffmann;Cell,2020
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Safety and Tolerability of COVID-19 Vaccine in Mast Cell Disorders Real-Life Data from a Single Centre in Italy;Vaccines;2024-02-16
2. Transcription Factor Driven Gene Regulation in COVID-19 Patients;Viruses;2023-05-18
3. Research and development of Chinese anti-COVID-19 drugs;Acta Pharmaceutica Sinica B;2022-12
4. Chemical Nature of Metals and Metal-Based Materials in Inactivation of Viruses;Nanomaterials;2022-07-08
5. Optimization of S-Nitrosocaptopril Monohydrate Storage Conditions Based on Response Surface Method;Molecules;2021-12-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3